Affymax, Takeda Announce Permanent J-Code for OMONTYS Injection In Effect
Affymax, Inc. (Nasdaq: AFFY) and Takeda Pharmaceuticals U.S.A., Inc. (TPUSA) today announced that the J-code assigned by the Centers for Medicare and Medicaid Services (CMS) for OMONTYS^® (peginesatide) Injection is now effective. This permanent OMONTYS-specific billing code, J0890, will continue to provide for streamlined reimbursement for dialysis organizations prescribing OMONTYS. OMONTYS is the only once-monthly erythropoiesis-stimulating agent (ESA) for anemia available to the adult dialysis patient population with chronic kidney disease (CKD) in the United States (U.S.).
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.